Rchr
J-GLOBAL ID：200901031556284521
Update date: Nov. 28, 2024
YAMADA Taketo
ヤマダ タケト | YAMADA Taketo
Affiliation and department：
Job title：
Professor
Research field (4)：
Other
, Clinical pharmacy
, Experimental pathology
, Human pathology
Research keywords (8)：
molecular pathology
, cancer
, molecular pathology
, model for human diseases
, 疾患モデル
, molecular target therapy
, 分子標的療法
, cancer
Research theme for competitive and other funds (51)：
- 2022 - 2024 Development of transportable scFV monoclonal antibody into nucleus
- 2021 - 2024 核内移行する抗体へのRNAポリメラーゼII阻害分子の結合によるがん分子標的療法の開発
- 2021 - 2024 悪性胸膜中皮腫に対するヒト化抗CD26抗体と免疫チェックポイント阻害薬との革新的併用療法の開発
- 2020 - 2024 The role of HDAC isoform regulating CD26 induction in relapsed or refractory multiple myeloma
- 2020 - 2024 新たな概念によるハイリスク骨髄腫の予後不良に関わる分子機構の探索と克服薬の開発
- 2019 - 2022 Novel anti-cancer therapy against super-enhancer using humanized monoclonal antibody with transportation activity into nucleus
- 2020 - 2021 核内移行する抗体へのRNAポリメラーゼII阻害分子の結合によるがん分子標的療法の開発
- 2019 - 2021 Development of ChIPseq method using pathological specimens and identification of disease-specific super-enhancer
- 2016 - 2019 Novel therapy against human cancers using intra-nuclear transportable humanized monoclonal antibody against CD26.
- 2018 - 現在 悪性胸膜中皮腫のヒト化CD26抗体療法確立のための予後・治療効果 予測バイオマーカーの開発
- 2015 - 2018 Regulation of human beta cell mass
- 2016 - 2018 免疫系ヒト化マウスを用いた癌免疫回避機構解明と次世代遺伝子ワクチンによる克服戦略
- 2015 - 2018 Establishment of novel combination therapy against mesothelioma using humanized anti-CD26 antibody.
- 2017 - 現在 ハイリスク造血器腫瘍の髄外病変に着目した新規ターゲットの探索と創薬研究
- 2014 - 2017 Drug discovery based on novel concept for overcoming high-risk myeloma which is still intractable despite of recent progress in the treatment
- 2014 - 2017 治療法の進歩からとり残された高リスク骨髄腫に対する新しいコンセプトによる創薬研究
- 2016 - 現在 難治性多発性骨髄腫のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発
- 2013 - 2016 難治性溶骨性骨転移のヒト化抗CD26モノクローナル抗体を用いた分子標的療法の開発
- 2012 - 2015 悪性中皮腫のヒト化CD26抗体療法の確立及び化学療法剤の有効性評価に有用な新規疾患関連バイオマーカーの開発
- 2013 - 2014 Development of molecular targeting therapy using nuclear-transpoted humanized monoclonal antibody
- 2011 - 2014 Human natural helper cells and its involvement in diseases
- 2010 - 2012 Basic research of defining the function of CD26 on human immune system and its clinical application for autoimmune diseases.
- 2009 - 2011 Analysis on molecular mechanism of anti-tumor effect of thalidomide and exploitation of novel agents to overcome therapy-resistant multiple myeloma
- 2008 - 2010 Mechanisms of infection of Helicobacter pylori in human.
- 2007 - 2007 悪性中皮腫の発生機構及び病態の解明
- 2005 - 2006 Establishment of in vivo model for angiogenesis in hematological malignancy and development of anti-angiogenic therapy.
- 2003 - 2005 Analysis on porcine immune system and generation of immunodeficient pig for the application to regeneration medicine
- 2003 - 2004 In vitro and in vivo growth suppression of HPV-related cancer cells by siRNA targeting E6 oncogene
- 2002 - 2003 Establishment of neuroblastoma regression model and molecular mechanisms
- 2002 - 2003 内分泌撹乱物質の人体汚染と腸肝循環および皮脂による代謝メカニズム
- 2002 - 2003 ヒト臓器を移植された新しいヒト疾患動物モデルの確立
- 2001 - 2003 Establishment of a novel mouse model for studying prostate cancer metastasis to human bone and new therapeutic strategies.
- 2001 - 2002 バイオマテリアルの生体内劣化とマクロファージ
- 2001 - 2002 Model for human tumor sngiogenesis using NOD/SCID mice
- 2001 - 2002 Development of bone regeneration therapy for osteoporosis using humanized mice
- 2001 - 2002 A basic study on the development of metallic biomaterials
- 2000 - 2002 Development of novel humanized-mice and application to regenerative medicine
- 2001 - 2001 骨髄間葉系幹細胞移植による創傷治癒促進の試み
- 2001 - 2001 日本における内分泌攪乱物質の人体汚染と腸肝循環について
- 2000 - 2000 低分子G蛋白、Rhoの創収縮における役割の解明
- 1999 - 2000 Study on apoprotein of the convulsion-inducing factor in schistosome egg granulomas
- 1999 - 2000 Model for human cancer invasion/metastasis using NOD/SCID mice
- 1998 - 2000 Molecular Pathology of Solid Tumors in Childhood
- 1998 - 1998 胎児性腫瘍の発症機構と器官形成の分子基盤の解明
- 1997 - 1998 Characterization of embryonic carcinoma-specific antigen 6E2
- 1997 - 1997 胎児性腫瘍の発症機構と器官形成の分子基盤の解明
- 1996 - 1997 Function of novel gene, EAT that is early gene induced by all-trans retinoic acid in human EC cells
- 1995 - 1995 ヒト胎児性癌細胞の分化とアポトーシスにおける熱ショック蛋白HSP90の機能解析
- 1995 - 1995 ヒト胎児制癌(EC)細胞の分化と細胞死の分子細胞学的機序
- 1993 - 1993 トランスジェニックマウスを用いたヒトG-CSFの生体内機能の解析
- 1991 - 1992 Molecular and Cell Biological Differentiation Capabilities on Human Germ Cell Tumor Cells
Show all
Papers (186)：
-
Hattori Y, Miyakawa Y, Yokoyama K, Yamada T, Du W, Jinzaki M, Shinmoto H, Okamoto S. Prospective Study of Combination Therapy with Low-Dose Thalidomide plus Prednisolone Ameliorating Cytopenia in Primary Myelofibrosis. International Journal of Hematology. 2111. 93. 1. 129-131
-
Wataru Hirata, Toshiaki Shinojima, Kotaro Yokota, Rei Kin, Taketo Yamada, Hirotaka Asakura. A Case of Testicular Cancer in a Long-term Hydranencephaly Survivor with Undescended Testes. IJU Case Reports. 2024
-
Nishida H, Suzuki R, Nakajima K, Hayashi M, Morimoto C, Yamada T. HDAC inhibition involves CD26 induction on myeloma cells via the c-Myc/Sp1- mediated promoter activation and restores therapeutic resistance to humanized antibody. Cancer Research Communications. 2024. 4. 2. 349-364
-
Kobayashi E, Kamihara Y, Arai M, Wada A, Kikuchi S, Hatano R, Iwao N, Susukida T, Ozawa T, Adachi Y, et al. Development of a Novel CD26-Targeted Chimeric Antigen Receptor T Cell Therapy for CD26-Expressing T Cell Malignancies. Cells. 2023. 12. 16. 2059
-
Okatama M, Fujimori K, Sato M, Samata K, Kurita K, Sugiyama H, Ichikawa D, Matsushita M, Suto Y, Iwasaki G, et al. GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c-MET tyrosine kinase. Cancer Med. 2023
ｍore...
MISC (18)：
-
Eriko Komiya-Suyama, Ryo Hatano, Haruna Otsuka, Takumi Itoh, Hiroto Yamazaki, Yasushi Suga, Utako Kimura, Taketo Ya-Mada, Mitsutoshi Tominaga, Kenji Takamori, et al. THE REGULATION OF PRURITUS IN PSORIASIS AND ATOPIC DERMATITIS - A POSSIBLE ROLE FOR CD26/DPPIV. ACTA DERMATO-VENEREOLOGICA. 2017. 97. 8. 1008-1009
-
Yuusuke Watanabe, Yoshifumi Saisho, Jun Inaishi, Rie Murakami, Tami Tsuchiya, Seiji Sato, Kinsei Kou, Minoru Kitago, Yuko Kitagawa, Taketo Yamada, et al. Effects of Obesity and Diabetes on Delta and Pancreatic Polypeptide Cell Mass and the Relative Change among Islet Endocrine Cell Mass in Humans. DIABETES. 2017. 66. A583-A583
-
Rie Murakami, Yoshifumi Saisho, Kinsei Kou, Seiji Sato, Jun Inaishi, Yuusuke Watanabe, Tami Tsuchiya, Minoru Kitago, Yuko Kitagawa, Taketo Yamada, et al. Relationship between Intrapancreatic Fat Content and Beta- and Alpha-Cell Mass in Humans With and Without Diabetes. DIABETES. 2017. 66. A577-A578
-
Hiroko Nishida, Hiroko Madokoro, Hiroshi Suzuki, Mutsumi Hayashi, Chikao Morimoto, Michiie Sakamoto, Taketo Yamada. CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma. BLOOD. 2015. 126. 23
-
Nobukazu Fujimoto, Kei Ohnuma, Keisuke Aoe, Osamu Hosono, Taketo Yamada, Takumi Kishimoto, Chikao Morimoto. Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma. JOURNAL OF THORACIC ONCOLOGY. 2015. 10. 9. S200-S200
ｍore...
Patents (8)：
-
抗ヒトCD26モノクローナル抗体
-
フェニルフタルイミド修飾体及びそれを有効成分とする抗癌剤
-
抗CD26抗体と他の抗癌剤とを組み合わせた癌治療用組成物
-
抗ヒトCD26モノクローナル抗体又はその抗原結合性断
-
サリドマイド誘導体を有効成分とする抗癌剤
ｍore...
Books (10)：
-
免疫染色の基礎:抗原賦活法、増感法、ラビット抗体「病理と臨床 38巻臨時増刊号 免疫組織化学」
文光堂 2020
-
免疫染色の基礎:抗原賦活法、増感法、ラビット抗体 病理と臨床 38巻臨時増刊号 免疫組織化学
文光堂 2020
-
The Use of the Humanized Anti-CD26 Monoclonal Antibody YS110A as a Novel Targeted Therapy for Refractory Cancers and Immune Disorders.,Advances in Medicine and Biology
Nova Science Publishers 2018
-
The Use of the Humanized Anti-CD26 Monoclonal Antibody YS110A as a Novel Targeted Therapy for Refractory Cancers and Immune Disorders. Advances in Medicine and Biology
Nova Science Publishers 2018
-
,The Use of the Humanized Anti-CD26 Monoclonal Antibody YS110A as a Novel Targeted Therapy for Refractory Cancers and Immune Disorders
Nova Science Publishers 2017
ｍore...
Lectures and oral presentations (67)：
-
本態性血小板血症患者に生じた、異型巨核球と組織球様細胞の浸潤が目立った皮膚生検の一例
(第102回日本病理学会関東支部学術集会 2024)
-
リンパ節転移が認められた腫瘍径1cm未満の直腸神経内分泌腫瘍(NET-G2)の1例
(第44回日本癌局所療法研究会 2022)
-
原発性腹膜癌(高異型度漿液性癌)の一例
(第63回日本臨床細胞学会総会(春期大会) 2022)
-
CD26陽性がんに対する新規抗体-抗がん剤結合分子ADCの開発
(第111回日本病理学会総会 2022)
-
Up-regulation of CD26 on multiple myeloma cells by HDAC inhibition augments the efficacy of humanized antibody
(The 63rd AMERICAN SOCIETY OF HEMATOLOGY(ASH) ANNUAL MEETING 2021)
ｍore...
Professional career (1)：
- Doctor of Philosophy in Medicine (Keio University)
Committee career (8)：
- 2009/04 - 現在 The Biomedical Society for Stress Response
- 2009/04 - 現在 臨床ストレス応答学会 学会評議員
- 2006/11 - 現在 臨床ストレス応答研究会 評議員
- 1992/04 - 現在 日本病理学会 学術評議員
- 1990/03 - 現在 日本病理学会 学術評議員
- 2010/10 - 2019/03 日本癌学会 JJCO編集委員
- 2013/10 - 2015/12 日本癌学会 評議員
- 2006/04 - 日本病理学会 Pathogy International編集委員
Show all
Association Membership(s) (6)：
The Biomedical Society for Stress Response
, 日本分子生物学会
, 日本免疫学会
, 日本癌学会
, 日本血液学会
, 日本病理学会
